Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | TNKS | O95271 | 1/20 | 0.57 |
| ▸ | PARP1 | P09874 | 1/20 | 0.57 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.52 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | PLD2 | O14939 | 1/20 | 0.51 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4749395 | 0.90 | CHRM1 (0.64) | OPRM1TNKSPARP1PARP2CHRM1 | |
| SCHEMBL8667070 | 0.86 | CHRM1 (0.70) | OPRM1TNKSPARP1PARP2CHRM1 | |
| SCHEMBL8349502 | 0.85 | OPRM1 (0.61) | OPRM1TNKSPARP1PARP2CHRM1 | |
| SCHEMBL22716913 | 0.85 | HSD11B1 (0.62) | OPRM1TNKSPARP1PARP2CHRM1 | |
| SCHEMBL27917794 | 0.85 | CHRM1 (0.67) | OPRM1TNKSPARP1PARP2CHRM1 | |
| SCHEMBL13823764 | 0.84 | OPRM1 (0.61) | OPRM1TNKSPARP1PARP2CHRM1 | |
| SCHEMBL3409721 | 0.84 | TNKS (0.49) | OPRM1TNKSPARP1PARP2CHRM1 | |
| SCHEMBL29198147 | 0.84 | CHRM1 (0.53) | OPRM1TNKSPARP1PARP2CHRM1 | |
| SCHEMBL6577611 | 0.83 | CHRM1 (0.63) | OPRM1TNKSPARP1PARP2CHRM1 | |
| SCHEMBL22587976 | 0.82 | HSD11B1 (0.62) | OPRM1TNKSPARP1PARP2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027132-B1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | claimed |
| EP-2027132-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-25 | — | — | EP | claimed |
| WO-2007134958-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | claimed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | claimed |
| EP-2027132-B1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | disclosed |
| EP-2027132-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007134958-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | ADORA2B, UTS2R, TBXA2R | OPRM1 3240/4885TNKS 1885/4885PARP1 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.